About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Krastm3Tyj
targeted mutation 3, Tyler Jacks
MGI:2136169
Summary 12 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
 		Krastm3Tyj/Krastm3Tyj involves: 129S4/SvJae MGI:3769019
ht2
 		Krastm3Tyj/Kras+ involves: 129S4/SvJae MGI:3770517
ht3
 		Krastm3Tyj/Kras+ involves: 129S4/SvJae * C57BL/6 MGI:3770516
cx4
 		Ccne1tm1Jro/?
Krastm3Tyj/? 		either: (involves: 129S4/SvJaeSor) or (involves: 129S4/SvJaeSor * C57BL/6) MGI:3586557
cx5
 		Eif4eGt(RRO036)Byg/Eif4e+
Krastm3Tyj/Kras+ 		involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N MGI:5708384
cx6
 		Krastm3Tyj/Kras+
Pik3catm1Jdo/Pik3catm1Jdo 		involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J MGI:3716661
cx7
 		Krastm3Tyj/Kras+
Tg(CAG-Mir21,-EGFP)#Eno/0 		involves: 129S4/SvJae * C3H * C57BL/6 MGI:5317786
cx8
 		Dmtf1tm1Cjs/Dmtf1tm1Cjs
Krastm3Tyj/Kras+ 		involves: 129S4/SvJae * C57BL/6 MGI:3770618
cx9
 		Dmtf1tm1Cjs/Dmtf1+
Krastm3Tyj/Kras+ 		involves: 129S4/SvJae * C57BL/6 MGI:3770617
cx10
 		Krastm3Tyj/Krastm3Tyj
Mir301tm1Yoli/Mir301tm1Yoli 		involves: 129S4/SvJae * C57BL/6J MGI:5823077
cx11
 		Slc25a11em1Syki/Slc25a11+
Krastm3Tyj/Kras+ 		involves: 129S * C57BL/6 MGI:6469642
cx12
 		Krastm3Tyj/Kras+
Mir21atm1.1Eno/Mir21atm1.1Eno 		involves: 129S/SvEv * 129S4/SvJae * C57BL/6 MGI:5317787


Genotype
MGI:3769019
hm1
Allelic
Composition		 Krastm3Tyj/Krastm3Tyj
Genetic
Background		 involves: 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm3Tyj mutation (2 available); any Kras mutation (84 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
endocrine/exocrine glands
increased T cell derived lymphoma incidence ( J:237900 )
• 32.3% incidence of thymic lymphomas by 18 weeks of age

integument
increased skin papilloma incidence ( J:237900 )
• 17.6% incidence of skin papillomas by 18 weeks of age

mortality/aging
premature death ( J:237900 )
• survival rate is 165+/-64 days

neoplasm
increased T cell derived lymphoma incidence ( J:237900 )
• 32.3% incidence of thymic lymphomas by 18 weeks of age
increased skin papilloma incidence ( J:237900 )
• 17.6% incidence of skin papillomas by 18 weeks of age
increased lung tumor incidence ( J:237900 )
• mice develop lung tumors at 18 weeks

respiratory system
increased lung tumor incidence ( J:237900 )
• mice develop lung tumors at 18 weeks

immune system
increased T cell derived lymphoma incidence ( J:237900 )
• 32.3% incidence of thymic lymphomas by 18 weeks of age

hematopoietic system
increased T cell derived lymphoma incidence ( J:237900 )
• 32.3% incidence of thymic lymphomas by 18 weeks of age




Genotype
MGI:3770517
ht2
Allelic
Composition		 Krastm3Tyj/Kras+
Genetic
Background		 involves: 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm3Tyj mutation (2 available); any Kras mutation (84 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:68981 )
• Background Sensitivity: mean age at death is ~250 days on pure 129/Sv background compared to 200 days on mixed background

neoplasm
increased T cell derived lymphoma incidence ( J:68981 )
• Background Sensitivity: ~30% of animals develop thymic lymphoma; incidence is higher than on pure 129/Sv background
increased skin papilloma incidence ( J:68981 )
• Background Sensitivity: about 40% of mice develop skin papillomas, with slightly higher incidence than on mixed 129 and C57BL/6 background
increased lung tumor incidence ( J:119477 )
• 100% of mice examined at 3-4 months of age have developed lung tumors

integument
increased skin papilloma incidence ( J:68981 )
• Background Sensitivity: about 40% of mice develop skin papillomas, with slightly higher incidence than on mixed 129 and C57BL/6 background

endocrine/exocrine glands
increased T cell derived lymphoma incidence ( J:68981 )
• Background Sensitivity: ~30% of animals develop thymic lymphoma; incidence is higher than on pure 129/Sv background

respiratory system
increased lung tumor incidence ( J:119477 )
• 100% of mice examined at 3-4 months of age have developed lung tumors

hematopoietic system
increased T cell derived lymphoma incidence ( J:68981 )
• Background Sensitivity: ~30% of animals develop thymic lymphoma; incidence is higher than on pure 129/Sv background

immune system
increased T cell derived lymphoma incidence ( J:68981 )
• Background Sensitivity: ~30% of animals develop thymic lymphoma; incidence is higher than on pure 129/Sv background

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
lung cancer DOID:1324 OMIM:211980
OMIM:608935
OMIM:612571
OMIM:612593
OMIM:614210
 J:68981




Genotype
MGI:3770516
ht3
Allelic
Composition		 Krastm3Tyj/Kras+
Genetic
Background		 involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm3Tyj mutation (2 available); any Kras mutation (84 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:68981 )
• Background Sensitivity: mean age at death is ~200 days

neoplasm
increased tumor incidence ( J:68981 )
• all animals at time of death/sacrifice have extensive tumor burden
• mice display a more rapid tumor phenotype than Krastm2Tyj heterozygotes
increased T cell derived lymphoma incidence ( J:68981 )
• Background Sensitivity: animals are prone to thymic lymphomas (seen in ~40% of animals)
increased skin papilloma incidence ( J:68981 )
• Background Sensitivity: animals are prone to skin papillomas (seen in ~20% of animals); tumors typically arising on ears and snout are predominantly pedunculated and show limited tendency to progress to squamous cell carcinoma
increased lung tumor incidence ( J:68981 )
• 100% of animals show multifocal tumors at time of death/sacrifice
• tumors are detectable at 1 week of age as small pleural nodules; multiplicity and size of tumors increases with age, and ultimately result in respiratory distress and death
• tumors range from mild hyperplasia/dysplasia to overt carcinoma; small lesions consist of hyperplastic alveolar epithelium
• in older mice, infrequent metastases to thoracic lymph nodes, the kidney and other visceral organs
increased lung adenoma incidence ( J:68981 )
• as lesions enlarge, they form small alveolar adenomas; some show areas of glandular differentiation
increased lung adenocarcinoma incidence ( J:68981 )
• 5-10% of tumors have features of well-differentiated human papillary adenocarcinoma

digestive/alimentary system
abnormal large intestine crypts of Lieberkuhn morphology ( J:68981 )
• mutants have multiple aberrant crypt foci (ACF) of the colon

endocrine/exocrine glands
abnormal large intestine crypts of Lieberkuhn morphology ( J:68981 )
• mutants have multiple aberrant crypt foci (ACF) of the colon
increased T cell derived lymphoma incidence ( J:68981 )
• Background Sensitivity: animals are prone to thymic lymphomas (seen in ~40% of animals)

integument
increased skin papilloma incidence ( J:68981 )
• Background Sensitivity: animals are prone to skin papillomas (seen in ~20% of animals); tumors typically arising on ears and snout are predominantly pedunculated and show limited tendency to progress to squamous cell carcinoma

respiratory system
increased lung tumor incidence ( J:68981 )
• 100% of animals show multifocal tumors at time of death/sacrifice
• tumors are detectable at 1 week of age as small pleural nodules; multiplicity and size of tumors increases with age, and ultimately result in respiratory distress and death
• tumors range from mild hyperplasia/dysplasia to overt carcinoma; small lesions consist of hyperplastic alveolar epithelium
• in older mice, infrequent metastases to thoracic lymph nodes, the kidney and other visceral organs
increased lung adenoma incidence ( J:68981 )
• as lesions enlarge, they form small alveolar adenomas; some show areas of glandular differentiation
increased lung adenocarcinoma incidence ( J:68981 )
• 5-10% of tumors have features of well-differentiated human papillary adenocarcinoma

immune system
increased T cell derived lymphoma incidence ( J:68981 )
• Background Sensitivity: animals are prone to thymic lymphomas (seen in ~40% of animals)

hematopoietic system
increased T cell derived lymphoma incidence ( J:68981 )
• Background Sensitivity: animals are prone to thymic lymphomas (seen in ~40% of animals)

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
lung cancer DOID:1324 OMIM:211980
OMIM:608935
OMIM:612571
OMIM:612593
OMIM:614210
 J:68981




Genotype
MGI:3586557
cx4
Allelic
Composition		 Ccne1tm1Jro/?
Krastm3Tyj/?
Genetic
Background		 either: (involves: 129S4/SvJaeSor) or (involves: 129S4/SvJaeSor * C57BL/6)
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ccne1tm1Jro mutation (0 available); any Ccne1 mutation (23 available)
Krastm3Tyj mutation (2 available); any Kras mutation (84 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:99695 )
• mean survival is reduced to 160 days compared to 260 days for mice homozygous for Kras alone

cellular
chromosome breakage ( J:99695 )
• 2 of 6 tumors from double mutants display significant gains or losses of whole chromosomes while no gains or losses of whole chromosomes are seen in Kras homozygotes




Genotype
MGI:5708384
cx5
Allelic
Composition		 Eif4eGt(RRO036)Byg/Eif4e+
Krastm3Tyj/Kras+
Genetic
Background		 involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Eif4eGt(RRO036)Byg mutation (0 available); any Eif4e mutation (42 available)
Krastm3Tyj mutation (2 available); any Kras mutation (84 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
decreased tumor growth/size ( J:224214 )
• smaller tumors of mice treated with piperlongumine than in Krastm3Tyj heterozygotes
decreased lung tumor incidence ( J:224214 )
• fewer tumors by 12 weeks with a more than 2-fold reduction in tumor burden compared with Krastm3Tyj heterozygotes

cellular
increased cellular sensitivity to oxidative stress ( J:224214 )
• in tumors of mice treated with piperlongumine
oxidative stress ( J:224214 )
• increased compared with Krastm3Tyj heterozygotes

respiratory system
decreased lung tumor incidence ( J:224214 )
• fewer tumors by 12 weeks with a more than 2-fold reduction in tumor burden compared with Krastm3Tyj heterozygotes




Genotype
MGI:3716661
cx6
Allelic
Composition		 Krastm3Tyj/Kras+
Pik3catm1Jdo/Pik3catm1Jdo
Genetic
Background		 involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm3Tyj mutation (2 available); any Kras mutation (84 available)
Pik3catm1Jdo mutation (1 available); any Pik3ca mutation (66 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
decreased incidence of induced tumors ( J:122866 )
• zero to two visible tumors are found compared to forty or so tumors in Krastm3Tyj mice
• apoptotic rates in small lesions are increased compared to in Krastm3Tyj mice
decreased lung tumor incidence ( J:122866 )
• one mouse did not show any evidence of lung tumor formation up to 6 months of age

respiratory system
decreased lung tumor incidence ( J:122866 )
• one mouse did not show any evidence of lung tumor formation up to 6 months of age




Genotype
MGI:5317786
cx7
Allelic
Composition		 Krastm3Tyj/Kras+
Tg(CAG-Mir21,-EGFP)#Eno/0
Genetic
Background		 involves: 129S4/SvJae * C3H * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm3Tyj mutation (2 available); any Kras mutation (84 available)
Tg(CAG-Mir21,-EGFP)#Eno mutation (0 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:164198 )
• mice exhibit premature death compared with wild-type mice
• however, mice exhibit the same mortality as Krastm3Tyj heterozygotes

neoplasm
increased tumor growth/size ( J:164198 )
• increased proliferation of tumor cells compared with tumor cells from Krastm3Tyj heterozygotes
increased lung tumor incidence ( J:164198 )
• at 18 weeks compared with Krastm3Tyj heterozygotes
• mice develop increased incidence of all tumor grades without increasing the rate of conversion to adenocarcinoma compared with Krastm3Tyj heterozygotes
decreased tumor incidence ( J:164198 )
• of thymic tumors compared with Krastm3Tyj heterozygotes

respiratory system
increased lung tumor incidence ( J:164198 )
• at 18 weeks compared with Krastm3Tyj heterozygotes
• mice develop increased incidence of all tumor grades without increasing the rate of conversion to adenocarcinoma compared with Krastm3Tyj heterozygotes




Genotype
MGI:3770618
cx8
Allelic
Composition		 Dmtf1tm1Cjs/Dmtf1tm1Cjs
Krastm3Tyj/Kras+
Genetic
Background		 involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Dmtf1tm1Cjs mutation (3 available); any Dmtf1 mutation (83 available)
Krastm3Tyj mutation (2 available); any Kras mutation (84 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:126002 )
• mean survival time of double mutants is 21 weeks compared to 35 weeks for Kras+/-, Dmtf1-sufficient mice

neoplasm
increased T cell derived lymphoma incidence ( J:126002 )
• ~20% of mice develop thymic lymphomas
increased skin papilloma incidence ( J:126002 )
• 10-20% of animals develop tail papillomas
increased lung adenoma incidence ( J:126002 )
• all mice develop lung adenomas or lung adenocarcinomas
increased lung adenocarcinoma incidence ( J:126002 )
• greater than 50% of mice develop lung carcinomas by 40 weeks of age, and tumors are significantly larger than those found in KrasLA+/- single mutants
• number of tumor nodules increase as animals become sick, with trend to increased nodule size
decreased tumor latency ( J:126002 )
• tumorigenesis is accelerated relative to heterozygous Kras, wild-type Dmtf1 mice

integument
increased skin papilloma incidence ( J:126002 )
• 10-20% of animals develop tail papillomas

endocrine/exocrine glands
increased T cell derived lymphoma incidence ( J:126002 )
• ~20% of mice develop thymic lymphomas

respiratory system
increased lung adenoma incidence ( J:126002 )
• all mice develop lung adenomas or lung adenocarcinomas
increased lung adenocarcinoma incidence ( J:126002 )
• greater than 50% of mice develop lung carcinomas by 40 weeks of age, and tumors are significantly larger than those found in KrasLA+/- single mutants
• number of tumor nodules increase as animals become sick, with trend to increased nodule size

immune system
increased T cell derived lymphoma incidence ( J:126002 )
• ~20% of mice develop thymic lymphomas

hematopoietic system
increased T cell derived lymphoma incidence ( J:126002 )
• ~20% of mice develop thymic lymphomas




Genotype
MGI:3770617
cx9
Allelic
Composition		 Dmtf1tm1Cjs/Dmtf1+
Krastm3Tyj/Kras+
Genetic
Background		 involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Dmtf1tm1Cjs mutation (3 available); any Dmtf1 mutation (83 available)
Krastm3Tyj mutation (2 available); any Kras mutation (84 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:126002 )
• mean survival time of double mutants is 21 weeks compared to 35 weeks for Kras+/-, Dmtf1-sufficient mice

neoplasm
increased T cell derived lymphoma incidence ( J:126002 )
• ~35% of mice develop thymic lymphomas
increased skin papilloma incidence ( J:126002 )
• 10-20% of animals develop tail papillomas
abnormal metastatic potential ( J:126002 )
• <5% of animals show distant metastases (liver/intr-abdominal or leg) of lung tumors, while no metastases are observed in KrasLA+/-, Dmtf1-sufficient mice
increased lung tumor incidence ( J:126002 )
• ~50% of largest tumors are well, moderately, or poorly differentiated adenocarcinomas, with signs of intrabronchial or intravascular invasion
increased lung adenoma incidence ( J:126002 )
• all mice develop lung adenomas or lung adenocarcinomas
increased lung adenocarcinoma incidence ( J:126002 )
• greater than 50% of mice develop lung carcinomas by 40 weeks of age, and tumors are significantly larger than those found in KrasLA+/- single mutants
• number of tumor nodules increase as animals become sick, with trend to increased nodule size
decreased tumor latency ( J:126002 )
• tumorigenesis is accelerated relative to heterozygous Kras, wild-type Dmtf1 mice

integument
increased skin papilloma incidence ( J:126002 )
• 10-20% of animals develop tail papillomas

endocrine/exocrine glands
increased T cell derived lymphoma incidence ( J:126002 )
• ~35% of mice develop thymic lymphomas

respiratory system
increased lung tumor incidence ( J:126002 )
• ~50% of largest tumors are well, moderately, or poorly differentiated adenocarcinomas, with signs of intrabronchial or intravascular invasion
increased lung adenoma incidence ( J:126002 )
• all mice develop lung adenomas or lung adenocarcinomas
increased lung adenocarcinoma incidence ( J:126002 )
• greater than 50% of mice develop lung carcinomas by 40 weeks of age, and tumors are significantly larger than those found in KrasLA+/- single mutants
• number of tumor nodules increase as animals become sick, with trend to increased nodule size

hematopoietic system
increased T cell derived lymphoma incidence ( J:126002 )
• ~35% of mice develop thymic lymphomas

immune system
increased T cell derived lymphoma incidence ( J:126002 )
• ~35% of mice develop thymic lymphomas




Genotype
MGI:5823077
cx10
Allelic
Composition		 Krastm3Tyj/Krastm3Tyj
Mir301tm1Yoli/Mir301tm1Yoli
Genetic
Background		 involves: 129S4/SvJae * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm3Tyj mutation (2 available); any Kras mutation (84 available)
Mir301tm1Yoli mutation (1 available); any Mir301 mutation (4 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
integument
decreased skin tumor incidence ( J:237900 )
• decreased incidence of skin papillomas (7.1% vs 17.6%) as compared to mice homozygous for Krastm3Tyj

mortality/aging
premature death ( J:237900 )
• increased survival rates (approx 262 days vs 166 days) as compared to mice homozygous for Krastm3Tyj

neoplasm
decreased tumor growth/size ( J:237900 )
• tumors are smaller in size when compared to tumors from mice homozygous for Krastm3Tyj
decreased skin tumor incidence ( J:237900 )
• decreased incidence of skin papillomas (7.1% vs 17.6%) as compared to mice homozygous for Krastm3Tyj
decreased lymphoma incidence ( J:237900 )
• decreased incidence of thymic lymphomas (21.4% vs 32.3%) as compared to mice homozygous for Krastm3Tyj
decreased lung tumor incidence ( J:237900 )
• decrease in number of lung tumors at 18 weeks as compared to mice homozygous for Krastm3Tyj although all mice develop lung tumor
• decreased incidence of thymic lymphomas (21.4% vs 32.3%) and skin papillomas (7.1% vs 17.6%)

respiratory system
decreased lung tumor incidence ( J:237900 )
• decrease in number of lung tumors at 18 weeks as compared to mice homozygous for Krastm3Tyj although all mice develop lung tumor
• decreased incidence of thymic lymphomas (21.4% vs 32.3%) and skin papillomas (7.1% vs 17.6%)




Genotype
MGI:6469642
cx11
Allelic
Composition		 Slc25a11em1Syki/Slc25a11+
Krastm3Tyj/Kras+
Genetic
Background		 involves: 129S * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm3Tyj mutation (2 available); any Kras mutation (84 available)
Slc25a11em1Syki mutation (0 available); any Slc25a11 mutation (22 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
decreased lung tumor incidence ( J:294965 )
• 60% reduction of number of tumor nodes at age 12 weeks
• 54% reduction in tumor area at age 12 weeks

respiratory system
decreased lung tumor incidence ( J:294965 )
• 60% reduction of number of tumor nodes at age 12 weeks
• 54% reduction in tumor area at age 12 weeks




Genotype
MGI:5317787
cx12
Allelic
Composition		 Krastm3Tyj/Kras+
Mir21atm1.1Eno/Mir21atm1.1Eno
Genetic
Background		 involves: 129S/SvEv * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm3Tyj mutation (2 available); any Kras mutation (84 available)
Mir21atm1.1Eno mutation (0 available); any Mir21a mutation (8 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
neoplasm ( J:164198 )
N
• unlike Krastm3Tyj heterozygotes, mice do not develop skin papillomas or lung adenomcarcinomas
increased T cell derived lymphoma incidence ( J:164198 )
• fewer than in Krastm3Tyj heterozygotes
decreased tumor growth/size ( J:164198 )
• mice exhibit decreased total tumor area relative to lung area compared with Krastm3Tyj heterozygotes
• however, tumor cell proliferation is the same as in Krastm3Tyj heterozygotes
increased lung adenoma incidence ( J:164198 )
• mice develop fewer lung adenoma than in Krastm3Tyj heterozygotes
decreased tumor incidence ( J:164198 )
• mice develop fewer thymic lymphoma, lung hyperplasia and lung adenomas than in Krastm3Tyj heterozygotes
decreased lung tumor incidence ( J:164198 )
• fewer lung adenoma than in Krastm3Tyj heterozygotes

respiratory system
increased lung adenoma incidence ( J:164198 )
• mice develop fewer lung adenoma than in Krastm3Tyj heterozygotes
decreased lung tumor incidence ( J:164198 )
• fewer lung adenoma than in Krastm3Tyj heterozygotes
lung epithelium hyperplasia ( J:164198 )
• mice develop fewer lung hyperplasia than in Krastm3Tyj heterozygotes

endocrine/exocrine glands
increased T cell derived lymphoma incidence ( J:164198 )
• fewer than in Krastm3Tyj heterozygotes

hematopoietic system
increased T cell derived lymphoma incidence ( J:164198 )
• fewer than in Krastm3Tyj heterozygotes

immune system
increased T cell derived lymphoma incidence ( J:164198 )
• fewer than in Krastm3Tyj heterozygotes




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory